Inhibikase Therapeutics(US:IKT)2025-11-14 21:25Financial Performance - The net loss for the quarter ended September 30, 2025, was $11.9 million, or $0.13 per share, compared to a net loss of $5.8 million, or $0.65 per share for the same quarter in 2024, indicating an increase in net loss of 105.2%[5] - The total net loss for the nine months ended September 30, 2025, was $35.5 million, or $0.40 per share, compared to a net loss of $15.4 million, or $2.03 per share for the same period in 2024, representing an increase of 130.5%[5] Cash and Securities - As of September 30, 2025, the company's cash, cash equivalents, and marketable securities totaled $77.3 million, down from $97.5 million as of December 31, 2024, representing a decrease of approximately 20.5%[4] Expenses - Research and development expenses for the quarter ended September 30, 2025, were $7.6 million, up from $4.2 million in the same quarter of 2024, reflecting an increase of 80.9%[6] - Selling, general and administrative expenses for the quarter ended September 30, 2025, were $5.6 million, compared to $1.6 million for the same quarter in 2024, marking an increase of 250%[8] - The company incurred a non-cash write-off of in-process research and development of $7.4 million for the nine months ended September 30, 2025, related to the acquisition of CorHepta[6] Clinical Development - The company plans to initiate its Phase 2b clinical study of IKT-001 in Pulmonary Arterial Hypertension (PAH) during the fourth quarter of 2025, with approximately 150 participants expected[3] Strategic Initiatives - The company appointed Timothy Pigot as Chief Commercial and Strategy Officer to enhance its strategic direction[7] - The company expects to present at the Jefferies Global Healthcare Conference in London on November 17, 2025, to discuss its developments and strategies[7] Liabilities - The total liabilities as of September 30, 2025, were $6.7 million, compared to $3.7 million as of December 31, 2024, indicating an increase of 79.5%[14]